Department of Thyroid and Breast Surgery, Wuhu Second People's Hospital, Wuhu, Anhui 24100, People's Republic of China.
Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China,
Int J Nanomedicine. 2018 Jun 28;13:3795-3803. doi: 10.2147/IJN.S159585. eCollection 2018.
Breast cancer is the most common malignancy and one of the main causes of death in women. Luminal B (HER2-) breast cancer subtype has been proposed since the 2011 St Gallon consensus. The hormone receptor status in this type of breast cancer is positive; thus, endocrine therapy was performed in all cases, but the treatment was not satisfactory, and a significant number of cases received very little benefit from chemotherapy. Furthermore, there is no effective treatment target for this subtype. Luminal B (HER2-) breast cancer subtype has been proposed since the 2011 St Gallon consensus. Therefore, the study of the key molecules in the microenvironment of breast cancer can help to reveal the biological characteristics.
Luminal B (HER2-) breast cancer is a subtype with higher heterogeneity and poorer prognosis than luminal A. It is known that the development of cancer cells is an active process, and this process needs microenvironment cytokines, including chemokine (C-C motif) ligand 5 (CCL5) and collagen IV. Therefore, CCL5 and collagen IV were imaged and detected by quantum dot, and the CCL5/collagen IV ratio was calculated to investigate the prognostic value of the CCL5/collagen IV ratio in luminal B (HER2-).
Quantitative determination showed a statistically significant negative correlation between CCL5 and collagen IV. The 5-year disease-free survival (5-DFS) of the high and low CCL5/collagen IV ratio subgroups was significantly different. The CCL5/collagen IV ratio had a greater prognostic value for 5-DFS. The CCL5/collagen IV ratio was an independent prognostic indicator.
Our findings revealed the effective integration of tumor CCL5 and collagen IV, and a new method for predicting the prognosis of luminal B (HER2-) has been developed.
乳腺癌是最常见的恶性肿瘤之一，也是女性死亡的主要原因之一。Luminal B（HER2-）乳腺癌亚型自 2011 年圣加仑共识以来已经提出。这种类型的乳腺癌激素受体状态为阳性；因此，所有病例均进行内分泌治疗，但治疗效果并不令人满意，相当多的病例从化疗中获益甚少。此外，这种亚型没有有效的治疗靶点。Luminal B（HER2-）乳腺癌亚型自 2011 年圣加仑共识以来已经提出。因此，研究乳腺癌微环境中的关键分子有助于揭示生物学特征。
Luminal B（HER2-）乳腺癌是一种异质性更高、预后更差的亚型，比 Luminal A 更差。已知癌细胞的发展是一个活跃的过程，这个过程需要微环境细胞因子，包括趋化因子（C-C 基序）配体 5（CCL5）和胶原 IV。因此，通过量子点对 CCL5 和胶原 IV 进行成像和检测，并计算 CCL5/胶原 IV 比值，以研究 CCL5/胶原 IV 比值在 Luminal B（HER2-）中的预后价值。
定量测定显示 CCL5 与胶原 IV 之间存在统计学上显著的负相关。高和低 CCL5/胶原 IV 比值亚组的 5 年无病生存率（5-DFS）差异有统计学意义。CCL5/胶原 IV 比值对 5-DFS 具有更大的预后价值。CCL5/胶原 IV 比值是独立的预后指标。
我们的研究结果揭示了肿瘤 CCL5 和胶原 IV 的有效整合，并为预测 Luminal B（HER2-）的预后提供了一种新方法。
